Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.71 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2594106 | 0.85 | EGFR (0.78) | EGFRGRM1ALDH1A1PDE3BPDE3A | |
| SCHEMBL2586027 | 0.84 | EGFR (0.65) | EGFRGRM1ESR2ESRRAALDH1A1 | |
| SCHEMBL14924051 | 0.84 | EGFR (0.54) | EGFRGRM1ESR2ESRRAALDH1A1 | |
| SCHEMBL2594507 | 0.83 | EGFR (0.55) | EGFRGRM1ESR2ESRRALCK | |
| SCHEMBL2588545 | 0.82 | EGFR (0.73) | EGFRGRM1ESR2ESRRAPDE3B | |
| SCHEMBL3058904 | 0.81 | ESR2 (0.62) | EGFRGRM1ESR2ESRRAALDH1A1 | |
| SCHEMBL2588516 | 0.79 | EGFR (0.51) | EGFRALDH1A1KDM4E | |
| SCHEMBL2589543 | 0.79 | EGFR (0.65) | EGFRESR2ESRRAKDM4EESR1 | |
| SCHEMBL2586137 | 0.78 | ESRRA (0.47) | EGFRGRM1ESRRAKDM4ENPC1 | |
| SCHEMBL21526719 | 0.75 | ALDH1A1 (0.53) | EGFRALDH1A1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| CN-103432133-B | The purposes of nuclear receptor binding agents | GTX公司 | 2016-08-10 | — | — | CN | disclosed |
| US-9078888-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078888-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | DALTON JAMES T (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2566330-A1 | NUCLEAR RECEPTOR BINDING AGENTS | Gtx, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140228-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140228-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | ESRRB, ESRRG, ESRRA | EGFR 2299/4885GRM1 924/4885ESR2 4/4885 |
| US-20130116277-A1 | ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS | AKR1C3, AKR1C1, AKR1C2 | EGFR 2700/4885GRM1 3452/4885ESR2 511/4885 |
| US-20090030036-A1 | Nuclear receptor binding agents | NR0B1, NR2E3, NR0B2 | EGFR 679/4885GRM1 386/4885ESR2 22/4885 |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP1, FABP4, ADIPOR2 | EGFR 3952/4885GRM1 841/4885ESR2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.